search
Back to results

a Comparison Between the Effects of Crystalloids and Colloids on Lung Ultrasound

Primary Purpose

Pulmonary Edema

Status
Not yet recruiting
Phase
Early Phase 1
Locations
Egypt
Study Type
Interventional
Intervention
hydroxyethyl starch in sodium chloride injection Brand Name: Voluven
saline solution
Sponsored by
Kasr El Aini Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Pulmonary Edema

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  1. Pregnant cases with preeclampsia: gestational age >32 weeks
  2. Singleton pregnancy
  3. Age above 18 years

Exclusion Criteria:

  1. Pregnant cases with preeclampsia: gestational age >32 weeks
  2. Singleton pregnancy
  3. Age above 18 years

Sites / Locations

  • Kasr Elainy

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Group (V)

Group (R)

Arm Description

Group (V): will receive hydroxyethyl starch (voluven) Pfizer Inc 500ml over 30 minutes

Group (R): will receive ringer acetate 500ml over 30 minutes

Outcomes

Primary Outcome Measures

changes in Lung ultrasound score
Alveolo-interstitial syndrome is assessed by the measurement of multiple B-lines

Secondary Outcome Measures

Full Information

First Posted
August 9, 2022
Last Updated
August 16, 2022
Sponsor
Kasr El Aini Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05505708
Brief Title
a Comparison Between the Effects of Crystalloids and Colloids on Lung Ultrasound
Official Title
a Comparison Between the Effects of Crystalloids and Colloids on Lung Ultrasound Score in Preeclamptic Patients Undergoing Spinal Anesthesia for Caesarean Section: a Randomized Double Blinded Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
December 5, 2022 (Anticipated)
Primary Completion Date
January 2023 (Anticipated)
Study Completion Date
March 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Kasr El Aini Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is designed to compare the effect of crystalloids and colloids on lung ultrasound score in preeclapmtic pregnant cases undergoing spinal anesthesia for caesarean section Objectives: To identify ideal fluid in order to maintain proper intravascular volume in preeclamptic patients that allows organ perfusion without causing lung congestion or pulmonary edema Hypothesis: the investigators hypothesize that colloids are better than crystalloids in maintaining good intravascular volume without affecting lung ultrasound score.
Detailed Description
Hypertensive disorders are the most common complications of pregnancy. They occur in 6-8% of pregnancies and account for approximately 15% of maternal deaths in the United States Pre-eclampsia is a pregnancy-specific syndrome of unknown etiology that is defined as systolic blood pressure (SBP) > 140 mmHg and/or diastolic blood pressure (DBP) > 90 mmHg presenting after 20 weeks of gestation with significant proteinuria (1) Because patients with pre-eclampsia may have significant intravascular volume deficit and reduced uteroplacental perfusion, it is prudent to administer fluids before any anesthetic interventions. (2) however it may increase their risk of developing pulmonary oedema (3) Colloids and crystalloids are two types of fluids that are used for fluid replacement, as volume expanders. Crystalloids are low-cost salt solutions (e.g. saline) with small molecules, which can move around easily when injected into the body. Colloids can be man-made (e.g. starches, dextrans, or gelatins), or naturally occurring (e.g. albumin or fresh frozen plasma (FFP)), and have bigger molecules, so stay in the blood for longer before passing to other parts of the body. (4) Women with pre-eclampsia lose protein through renal excretion and may also extravasate protein into the interstitial tissues, oncotic pressure falls because of this and the tendency to lose fluid from the intravascular space is partially determined by this mechanism. Filling the vascular space with fluid will lead to increasing peripheral oedema. Colloids will remain in the vascular compartment for longer periods than crystalloids although the loss of colloid into the interstitial tissues will also contribute to the development of oedema. Changes in capillary permeability will have an independent influence. (5) Ultrasound is now widely used in many medical specialties, being safe tool for both the parturient and the baby, ultrasound is basically used by the obstetricians in pregnant females for diagnosis of fetal presentation, placental position, fetal organs, amount of liquor and in some interventions amniocentesis. In the last 15 years, a new imaging application of sonography has emerged in the clinical arena: lung ultrasound (LUS), it can give valuable data in diagnosing and management of pneumothorax, pleural effusion, lung consolidation and pulmonary congestion. (6) The electrical cardiometry which can be used to measure and calculate hemodynamic parameters such as cardiac output, stroke volume, systemic vascular resistance, ICON (index of contractility), and thoracic fluid content. (7) In general, there is no epidemiological evidence to support the choice of colloidal solutions over crystalloids and it is not clear that colloidal solutions would be more effective and less likely to cause harm than crystalloids in preeclamptic patients. A meta-analysis was done to investigate crystalloid versus colloid resuscitation in critically ill patients however pregnant women and neonates were excluded. (8) Consequently, there is inadequate evidence supporting one view or another in the management of pre-eclampsia.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pulmonary Edema

7. Study Design

Primary Purpose
Prevention
Study Phase
Early Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
44 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Group (V)
Arm Type
Active Comparator
Arm Description
Group (V): will receive hydroxyethyl starch (voluven) Pfizer Inc 500ml over 30 minutes
Arm Title
Group (R)
Arm Type
Active Comparator
Arm Description
Group (R): will receive ringer acetate 500ml over 30 minutes
Intervention Type
Drug
Intervention Name(s)
hydroxyethyl starch in sodium chloride injection Brand Name: Voluven
Other Intervention Name(s)
starch
Intervention Description
(6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection) is a clear to slightly opalescent, colorless to slightly yellow, sterile, non-pyrogenic, isotonic solution for intravenous administration using sterile equipment. Each 100 mL of the solution contains: 6 g of Hydroxyethyl Starch 130/0.4 and 900 mg of Sodium Chloride USP in Water for Injection USP. In addition, sodium hydroxide, USP, or Hydrochloric acid, USP, has been added to adjust the final pH so the final solution pH is 4.0 to 5.5.
Intervention Type
Drug
Intervention Name(s)
saline solution
Other Intervention Name(s)
normal saline
Intervention Description
Within each 100 mL of 0.9% sodium chloride Injection USP, there is 15.4 mEq of sodium ions and 15.4 mEq of chloride ions. Additionally, the osmolarity is 308 mOsmol/liter, and it has a pH range of 4.5 to 7
Primary Outcome Measure Information:
Title
changes in Lung ultrasound score
Description
Alveolo-interstitial syndrome is assessed by the measurement of multiple B-lines
Time Frame
changes in lung ulrasound is measured by comparing the alvelo interstitial score at baseline (before ) receiving spinal anaesthesia then after 30 minutes

10. Eligibility

Sex
Female
Gender Based
Yes
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Pregnant cases with preeclampsia: gestational age >32 weeks Singleton pregnancy Age above 18 years Exclusion Criteria: Pregnant cases with preeclampsia: gestational age >32 weeks Singleton pregnancy Age above 18 years
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
karim abou elella, master
Phone
01002290779
Email
dr.kimo1989@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
abd elbar, MD
Organizational Affiliation
kasr alainy hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kasr Elainy
City
Cairo
Country
Egypt

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
No individual participant data will be shared. Results will be published by the investigators in academic journals. Sharing of generated study data will be carried out in several different ways. We plan to make our results available to researchers and potential collaborators interested
IPD Sharing Time Frame
Data requests can be submitted starting 9 months after article publication and the data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis.
IPD Sharing Access Criteria
Access to trial IPD can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information or to submit a request, please contact clinicalresearchsupportcenter@ucdenver.edu."
IPD Sharing URL
http://clinicalresearchsupportcenter@ucdenver.edu

Learn more about this trial

a Comparison Between the Effects of Crystalloids and Colloids on Lung Ultrasound

We'll reach out to this number within 24 hrs